GLP-1 RAs also were associated with significantly reduced risks of all-cause mortality (BMI <25: 7.6% vs 11.3%; HR 0.64; 95% CI, 0.52-0.79; BMI ≥25: 5.2% vs 8.3%; HR, 0.61; 95% CI, 0.53-0.71), admissions due to infections (BMI <25: 15.7% vs 17.8%; SHR, 0.85; 95% CI, 0.72-0.99; BMI ≥25: 14.1% vs 16.4%; SHR, 0.84; 95% CI, 0.76-0.92), and admissions due to any cause (BMI <25: 32.7% vs 35.0%; SHR, 0.89; 95% CI, 0.79-0.99; BMI ≥25: 33.2% vs 34.4%; SHR 0.92; 95% CI, 0.87-0.99) in both BMI groups compared with patients using DPP-4 inhibitors (Table 2). The gene discussed is GLP1R; the disease is infection.